Literature DB >> 23700138

Serum lactonase and arylesterase activities in alcoholic hepatitis and hepatitis B.

Mukund Ramchandra Mogarekar1, Swati Jitendra Talekar.   

Abstract

BACKGROUND: PON1 is an HDL-associated enzyme having antioxidant activity. PON1 is synthesized in the liver, and there is decreased synthesis of PON1 with increased lipid peroxidation. The study was carried with the aim of establishing whether chronic liver disease (CLD) produced any significant changes in serum arylesterase (AE) and lactonase activities of PON. The second objective was to determine whether there was any correlation between serum AE and lactonase activities and the various routine liver function tests. The usefulness of adding serum lactonase and AE activity to standard liver function tests was analyzed by multiple logistic regression analysis. Finally, the diagnostic efficacy or analytical performance of AE and lactonase in assessing patients with CLD was determined using 'receiver operating characteristic' (ROC) plot.
METHODS: The study group consisted of 120 subjects; 60 were patients with liver disease out of which 40 were having chronic alcoholic liver disease and 20, acute viral hepatitis B, and 60 were healthy controls. Serum PON1 lactonase activity was measured manually using dihydrocoumarin, and AE activity was measured using phenylacetate as substrate. Liver function tests (bilirubin, albumin, AST, ALT, alkaline phosphatise) were done by standard technique. RESULT: The serum lactonase and AE activities were decreased significantly in patients with chronic alcoholic liver disease (p < 0.001, p < 0.001) and acute viral hepatitis B (p < 0.001, p < 0.001). Both measurements showed higher efficiency in testing liver dysfunction in multivariate regression analysis. Model 1 consisted of bilirubin, albumin, AST, ALT, and alkaline phosphatase, R2 = 0.912. Model 2 consisted of model 1+arylesterase having higher R2 = 0.0.954, and model 3 consisted of model 1+lactonase having R2 = 0.962. ROC plots demonstrated a high diagnostic accuracy for serum PON1 lactonase (area under ROC curve = 0.982) and serum PON1 arylesterase (area under ROC curve = 0.986).
CONCLUSION: Low PON1 lactonase and AE activity were found in acute viral hepatitis B and in chronic alcoholic hepatitis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23700138     DOI: 10.1007/s12664-013-0334-1

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  17 in total

1.  A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration.

Authors:  T Kujiraoka; T Oka; M Ishihara; T Egashira; T Fujioka; E Saito; S Saito; N E Miller; H Hattori
Journal:  J Lipid Res       Date:  2000-08       Impact factor: 5.922

Review 2.  Current concepts in the pathogenesis of alcoholic liver injury.

Authors:  H Tsukamoto; S C Lu
Journal:  FASEB J       Date:  2001-06       Impact factor: 5.191

3.  Serum arylesterase and paraoxonase activity in patients with chronic hepatitis.

Authors:  Suleyman Sirri Kilic; Suleyman Aydin; Nermin Kilic; Fazilet Erman; Suna Aydin; Ilhami Celik
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

4.  The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment.

Authors:  Judit Marsillach; Gerard Aragonès; Raul Beltrán; Joan Caballeria; Juan Pedro-Botet; Carlos Morcillo-Suárez; Arcadi Navarro; Jorge Joven; Jordi Camps
Journal:  Clin Biochem       Date:  2008-10-21       Impact factor: 3.281

5.  Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage.

Authors:  Natàlia Ferré; Jordi Camps; Eduard Prats; Elisabet Vilella; Antoni Paul; Lídia Figuera; Jorge Joven
Journal:  Clin Chem       Date:  2002-02       Impact factor: 8.327

6.  The human serum paraoxonase/arylesterase polymorphism.

Authors:  H W Eckerson; C M Wyte; B N La Du
Journal:  Am J Hum Genet       Date:  1983-11       Impact factor: 11.025

7.  Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.

Authors:  M Aviram; M Rosenblat; C L Bisgaier; R S Newton; S L Primo-Parmo; B N La Du
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

8.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family.

Authors:  S L Primo-Parmo; R C Sorenson; J Teiber; B N La Du
Journal:  Genomics       Date:  1996-05-01       Impact factor: 5.736

9.  Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters.

Authors:  S Billecke; D Draganov; R Counsell; P Stetson; C Watson; C Hsu; B N La Du
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

Review 10.  Genetic variability in the cytochrome P450-paraoxonase 1 (PON1) pathway for detoxication of organophosphorus compounds.

Authors:  Clement E Furlong
Journal:  J Biochem Mol Toxicol       Date:  2007       Impact factor: 3.642

View more
  6 in total

1.  Silencing of EPCAM suppresses hepatic fibrosis and hepatic stellate cell proliferation in mice with alcoholic hepatitis via the PI3K/Akt/mTOR signaling pathway.

Authors:  Zhi Zhang; Huiqing Wen; Jun Weng; Lei Feng; Hongya Liu; Xiaojun Hu; Fanhong Zeng
Journal:  Cell Cycle       Date:  2019-08-05       Impact factor: 4.534

2.  Effect of PON1 gene polymorphisms in Turkish patients with hepatocellular carcinoma.

Authors:  Hikmet Akkız; Sedef Kuran; Ersin Akgöllü; Oğuz Üsküdar; Aynur Bekar; Süleyman Bayram; Selçuk Yıldırım; Yakup Ülger; Berrin Yalınbaş Kaya; Mahmut Şansal; Ercan Çınar
Journal:  Meta Gene       Date:  2013-10-28

3.  A Multi-Omics Analysis of PON1 Lactonase Activity in Relation to Human Health and Disease.

Authors:  Boštjan Petrič; Tanja Kunej; Aljoša Bavec
Journal:  OMICS       Date:  2020-12-11

Review 4.  Serum paraoxonase 1 (PON1) measurement: an update.

Authors:  Jose J Ceron; Fernando Tecles; Asta Tvarijonaviciute
Journal:  BMC Vet Res       Date:  2014-03-25       Impact factor: 2.741

5.  Impacts on Sirtuin Function and Bioavailability of the Dietary Bioactive Compound Dihydrocoumarin.

Authors:  Jennifer L Jacobi; Bo Yang; Xu Li; Anna K Menze; Sara M Laurentz; Elsa M Janle; Mario G Ferruzzi; George P McCabe; Clint Chapple; Ann L Kirchmaier
Journal:  PLoS One       Date:  2016-02-16       Impact factor: 3.240

6.  Association of Paraoxonase 1 Gene Polymorphisms With the Risk of Hepatitis B Virus-related Liver Diseases in a Guangxi Population: A Case-control Study.

Authors:  Xianjun Lao; Xiaogang Wang; Yanqiong Liu; Yu Lu; Dongmei Yang; Minyan Liu; Xiaolian Zhang; Chengzhi Rong; Xue Qin; Shan Li
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.